ABIONYX Pharma SA(DE:609)
€1.53+0.06 (+5.07%)
DE:609
ABIONYX Pharma SA financials statements
€1.53
At close:+0.06 (+5.07%)
ABIONYX Pharma SA (609) Ratios
0 Followers
ABIONYX Pharma SA Ratios
DE:609's free cash flow for Q2 2026 was €-2.09M. For the 2026 fiscal year, DE:609's free cash flow was decreased by €-50.00K and operating cash flow was €-2.04M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.06 | 1.58 | 1.75 | 1.49 | 1.93 |
| Quick Ratio | 1.01 | 1.52 | 1.70 | 1.46 | 1.90 |
| Cash Ratio | 0.68 | 0.87 | 1.05 | 0.79 | 1.18 |
| Solvency Ratio | -0.58 | -0.65 | -0.53 | -0.47 | -0.51 |
| Operating Cash Flow Ratio | -0.57 | -0.97 | -0.94 | -0.66 | -0.99 |
| Short-Term Operating Cash Flow Coverage | -6.47 | -4.27 | -7.31 | -6.84 | -10.25 |
| Net Current Asset Value | € -3.14M | € -167.00K | € -26.00K | € -1.08M | € 1.86M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.30 | 0.23 | 0.23 | 0.25 | 0.23 |
| Debt-to-Equity Ratio | 0.89 | 0.42 | 0.43 | 0.56 | 0.46 |
| Debt-to-Capital Ratio | 0.47 | 0.29 | 0.30 | 0.36 | 0.32 |
| Long-Term Debt-to-Capital Ratio | 0.32 | 0.08 | 0.12 | 0.16 | 0.13 |
| Financial Leverage Ratio | 3.02 | 1.81 | 1.87 | 2.21 | 2.04 |
| Debt Service Coverage Ratio | -7.68 | -4.27 | -9.23 | -3.49 | -9.56 |
| Interest Coverage Ratio | -31.27 | -91.34 | -179.58 | -17.12 | -48.00 |
| Debt to Market Cap | 0.02 | 0.04 | 0.04 | 0.04 | 0.04 |
| Interest Debt Per Share | 0.11 | 0.09 | 0.12 | 0.15 | 0.20 |
| Net Debt to EBITDA | -0.05 | 0.03 | 0.15 | 0.01 | 0.40 |
| Profitability Margins | |||||
| Gross Profit Margin | 9.25% | 18.35% | 13.32% | 12.11% | 38.37% |
| EBIT Margin | -153.95% | -117.52% | -100.95% | -78.92% | -1116.59% |
| EBITDA Margin | -140.39% | -107.13% | -104.40% | -76.35% | -1098.96% |
| Operating Profit Margin | -153.95% | -121.13% | -73.53% | -78.24% | -881.78% |
| Pretax Profit Margin | -153.53% | -118.85% | -75.82% | -80.08% | -862.52% |
| Net Profit Margin | -136.60% | -95.65% | -75.82% | -80.08% | -862.52% |
| Continuous Operations Profit Margin | -136.60% | -95.65% | -75.82% | -80.08% | -862.52% |
| Net Income Per EBT | 88.97% | 80.48% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 99.73% | 98.12% | 103.11% | 102.36% | 97.82% |
| Return on Assets (ROA) | -43.14% | -32.71% | -23.72% | -26.58% | -26.67% |
| Return on Equity (ROE) | -130.25% | -59.27% | -44.41% | -58.67% | -54.53% |
| Return on Capital Employed (ROCE) | -81.22% | -57.18% | -31.28% | -38.30% | -39.46% |
| Return on Invested Capital (ROIC) | -65.53% | -41.03% | -29.10% | -23.16% | -36.88% |
| Return on Tangible Assets | -74.79% | -55.03% | -37.52% | -40.56% | -35.55% |
| Earnings Yield | -4.12% | -10.97% | -9.29% | -8.73% | -9.57% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.56 | 2.00 | 1.86 | 4.05 | 0.43 |
| Payables Turnover | 2.42 | 2.27 | 2.79 | 2.49 | 0.15 |
| Inventory Turnover | 14.46 | 17.54 | 18.20 | 31.40 | 2.35 |
| Fixed Asset Turnover | 2.26 | 2.32 | 2.09 | 2.05 | 0.22 |
| Asset Turnover | 0.32 | 0.34 | 0.31 | 0.33 | 0.03 |
| Working Capital Turnover Ratio | 3.31 | 1.80 | 1.71 | 1.20 | 0.11 |
| Cash Conversion Cycle | 17.15 | 42.22 | 85.73 | -44.76 | -1369.65 |
| Days of Sales Outstanding | 142.48 | 182.10 | 196.27 | 90.14 | 848.42 |
| Days of Inventory Outstanding | 25.24 | 20.81 | 20.06 | 11.62 | 155.30 |
| Days of Payables Outstanding | 150.57 | 160.70 | 130.59 | 146.52 | 2373.38 |
| Operating Cycle | 167.72 | 202.92 | 216.32 | 101.76 | 1003.72 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.08 | -0.11 | -0.13 | -0.12 | -0.27 |
| Free Cash Flow Per Share | -0.09 | -0.11 | -0.13 | -0.13 | -0.28 |
| Dividend Paid and CapEx Coverage Ratio | -12.12 | -47.37 | -28.45 | -19.19 | -40.31 |
| Capital Expenditure Coverage Ratio | -12.12 | -47.37 | -28.45 | -19.19 | -40.31 |
| Operating Cash Flow Coverage Ratio | -0.77 | -1.16 | -1.09 | -0.84 | -1.35 |
| Operating Cash Flow to Sales Ratio | -0.72 | -0.78 | -0.80 | -0.64 | -9.91 |
| Free Cash Flow Yield | -2.36% | -8.98% | -10.11% | -7.34% | -11.27% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -23.69 | -9.11 | -10.76 | -11.45 | -10.45 |
| Price-to-Sales (P/S) Ratio | 33.12 | 8.72 | 8.16 | 9.17 | 90.12 |
| Price-to-Book (P/B) Ratio | 31.58 | 5.40 | 4.78 | 6.72 | 5.70 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -42.38 | -11.14 | -9.89 | -13.63 | -8.87 |
| Price-to-Operating Cash Flow Ratio | -45.88 | -11.14 | -10.24 | -14.34 | -9.09 |
| Price-to-Earnings Growth (PEG) Ratio | -1.03 | -1.09 | 0.54 | 0.33 | -0.06 |
| Enterprise Value Multiple | -23.64 | -8.11 | -7.67 | -12.00 | -7.80 |
| Enterprise Value | 134.86M | 39.96M | 37.15M | 48.13M | 57.85M |
| EV to EBITDA | -23.64 | -8.11 | -7.67 | -12.00 | -7.80 |
| EV to Sales | 33.19 | 8.69 | 8.01 | 9.16 | 85.71 |
| EV to Free Cash Flow | -42.47 | -11.10 | -9.70 | -13.62 | -8.44 |
| EV to Operating Cash Flow | -45.98 | -11.10 | -10.05 | -14.33 | -8.65 |
| Tangible Book Value Per Share | -0.03 | 0.06 | 0.08 | 0.06 | 0.21 |
| Shareholders’ Equity Per Share | 0.12 | 0.22 | 0.27 | 0.26 | 0.43 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.11 | 0.20 | 0.00 | 0.35 | -0.00 |
| Revenue Per Share | 0.11 | 0.14 | 0.16 | 0.19 | 0.03 |
| Net Income Per Share | -0.16 | -0.13 | -0.12 | -0.15 | -0.23 |
| Tax Burden | 0.89 | 0.80 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.01 | 0.75 | 1.01 | 0.77 |
| Research & Development to Revenue | 0.37 | 0.65 | 0.63 | 0.49 | 8.41 |
| SG&A to Revenue | 1.13 | 0.28 | 0.24 | 0.23 | 0.75 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.10 | 1.21 |
| Income Quality | 0.53 | 0.82 | 1.05 | 0.80 | 1.15 |
Currency in EUR
